Alzheon Revives Failed Alzheimer's Drug With Genetic Subtype Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.